Concepedia

Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis

Jukka Rintala, Johanna Savikko, Sini E. Rintala, Niina Palin, Petri Koskinen

Journal of Nephrology · 2015 · 13 citations · 15 references

DOI

Abstract

These results indicate that erlotinib prevents the early events of experimental mesangial proliferative glomerulonephritis. Therefore, inhibition of the EGF receptor with erlotinib could prevent the progression of glomerulonephritis also in clinical nephrology.

References

15

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.8K citations

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

Federico Cappuzzo, Tudor–Eliade Ciuleanu, Lilia Stelmakh et al. · The Lancet Oncology · 2010 · 1.2K citations · Full text

, , +7

Early role of Fsp1 in epithelial-mesenchymal transformation

Hirokazu Okada, Theodore M. Danoff, Raghu Kalluri et al. · American Journal of Physiology-Renal Physiology · 1997 · 429 citations

Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis

Guillaume Bollée, Martin Flamant, Sandra Schordan et al. · Nature Medicine · 2011 · 233 citations

, , +17

Immunocytochemical localization of human epidermal growth factor/urogastrone in several human tissues.

A. G. Kasselberg, David N. Orth, Mary E. Gray et al. · Journal of Histochemistry & Cytochemistry · 1985 · 233 citations · Full text

, , +17